These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38371630)

  • 1. PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China.
    Chen J; Zhang M; Li K; Duan Y; Zeng J; Li Q; Wang D; Song L; Li Q; Yin R
    Front Oncol; 2024; 14():1336616. PubMed ID: 38371630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
    Zhang D; Li S; Zhang X; Peng J; Zhang S
    Front Oncol; 2022; 12():955124. PubMed ID: 36059631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China.
    Chen J; Zhang M; Li K; Duan Y; Lin X; Zhong L; Li Q; Yin R
    Front Oncol; 2023; 13():1300199. PubMed ID: 38260846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
    Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
    Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
    Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China.
    Wang D; Shi X; Pei J; Zhang C; Peng L; Zhang J; Zheng J; Peng C; Huang X; Liu X; Liu H; Zhang G
    Chin Med J (Engl); 2024 Apr; ():. PubMed ID: 38679485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
    Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Overtreatment and Cost Effectiveness of Primary
    Rose PG; Yao M; Chambers LM; Mei L; Le P
    Gynecol Obstet (Sunnyvale); 2021; 11(9):. PubMed ID: 34925959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004).
    Kim NK; Kim Y; Kim HS; Park SJ; Hwang DW; Lee SJ; Yoo JG; Chang SJ; Son JH; Kong TW; Kim J; Shim SH; Lee AJ; Suh DH; Lee YY
    Cancer Med; 2023 Oct; 12(19):19449-19459. PubMed ID: 37768030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    Wang DF; Shi XW; Zhang C; Zhang J; Liu H; Huang JM; Zhang GN; Wen QL
    Gynecol Oncol; 2023 Mar; 170():25-31. PubMed ID: 36608384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
    Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
    Cao Y; Chen H; Huang Y; Hu H
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
    Zhou S; Jiang Y; Luo C; Yuan L
    Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.